Next expected deadline: TBA

Value & Term

Up to a maximum of $100,000 per year, for up to 3 years.

What is the Alberta/Novartis Translational Research Fund Opportunity?

The Alberta/Novartis Translational Research Fund Opportunity is a partnership between Novartis Pharmaceuticals Canada Inc. (Novartis), Alberta Innovates – Health Solutions (AIHS), and the Government of Alberta. This partnership will provide opportunities to develop projects that focus on Multiple Sclerosis (MS) and provide a better understanding of the disease and care of MS patients.

What are the objectives of the Alberta/Novartis Translational Research Fund Opportunity?

The Alberta/Novartis Translational Research Fund Opportunity supports translational research and innovation projects with a strong potential to advance Multiple Sclerosis (MS) patient care and/or research over the short or medium term (three to five years). The Opportunity will support the development of research and innovation projects in the priority topic areas identified by Novartis and the province of Alberta (see sidebar).

Preference will be given to research projects focused on priority topic area 1, Development and Implementation of Evidence-based Care (see sidebar).

What opportunity does the Alberta/Novartis Translational Research Fund provide?

This translational research opportunity provides up to $100,000 per year for a maximum of three years, non-renewable. Release of funds will be based on an agreed upon set of objectives, milestones and expenditures and the submission of semi-annual reports outlining progress.

Eligible expenses include:

  • Salaries of research personnel essential to the project (excluding the principal applicant’s and co-principal applicant(s), if applicable), including the support of graduate and post-graduate trainees;
  • Purchase and/or leasing of equipment required and justified in the project for funding;
  • Research material (including cost for access to data) required for the research project.

What is the application process?

The application process for the Alberta/Novartis Translational Research Fund Opportunity will be a two phase process consisting of a Letter of Intent (LOI, Phase 1) and a Full Application (Phase 2).

Important: Please review the Alberta/Novartis Translational Research Fund Opportunity Program Guide (2014/2015) before applying.

What is the review process?

LOIs and Full Applications will be assessed by an expert review committee appointed by AIHS, based on recommendations from the Alberta/Novartis Translational Research Fund Steering Committee. The review committee will have a proven track record of scientific, clinical care, commercialization and translational research expertise in the area of MS. AIHS may solicit additional scientific review or relevant advice by external expert reviewers as well as input from collaborative partners regarding relevance of proposed activities to the scope of the program.

 

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

For more information:
Disa Brownfield-Walker, Manager, Industry &Technology Initiatives
Disa.Brownfield-Walker@albertainnovates.ca
(780) 429-9329

Mike Christen, Officer, Grants Processing
Mike.Christen@albertainnovates.ca
(780) 809-2557

Quick Downloads

 

Priority Topic Areas

  • Development and Implementation of Evidence-based Care
  • Delivery of Patient Care
  • Advancement of MS Research and Innovation
  • Patient Engagement

Recent Decisions

04/11/2015
June 2015 Alberta/Novartis Translational Research Fund Opportunity – Full Application »

02/04/2015
February 2015 Alberta/Novartis Translational Research Fund Opportunity – Letter of Intent »

View more recent decisions »